Identification of emulsification proteins released from the cells by inhibiting the synthesis of GPI-anchor or β-1,3-glucan in Candida albicans [PDF]
Journal of Microbiological Methods.
Azuma, Masayuki +5 more
core +1 more source
Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source
Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
The prevalence of invasive pulmonary aspergillosis (IPA) is growing in critically ill patients in the intensive care unit (ICU). It is increasingly recognized in immunocompetent hosts and immunocompromised ones. IPA frequently complicates both severe influenza and severe coronavirus disease 2019 (COVID‐19) infection.
Sarah Gaffney +4 more
wiley +1 more source
Antifungal chemotherapies and immunotherapies for the future
Abstract Human fungal pathogens cause a broad plethora of infections, spanning cutaneous dermatophytoses to invasive infections in immunocompromised hosts. As eukaryotic pathogens are capable of morphotype switching, they present unique challenges both for drug development and the immunological response.
Darius Armstrong‐James
wiley +1 more source
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
Enhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
Manogepix is a broad-spectrum antifungal agent that inhibits glycosylphosphatidylinositol (GPI) anchor biosynthesis. Using whole-genome sequencing, we characterized two efflux-mediated mechanisms in the fungal pathogens Candida albicans and Candida parapsilosis that resulted in decreased ...
Sean D. Liston +4 more
openaire +2 more sources
In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination [PDF]
Manogepix (APX001A) is the active moiety of the drug candidate fosmanogepix (APX001), currently in clinical development for the treatment of invasive fungal infections. We compared manogepix EUCAST minimum effective concentrations (MECs) to MICs of five comparators and CLSI MECs and MICs by a colorimetric method against contemporary molds.
Karin Meinike Jørgensen +2 more
openaire +6 more sources
Candida auris in Austria—What Is New and What Is Different
Candida auris is a novel and emerging pathogenic yeast which represents a serious global health threat. Since its first description in Japan 2009, it has been associated with large hospital outbreaks all over the world and is often resistant to more than
Kathrin Spettel +10 more
doaj +1 more source
Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field
Acute lymphoblastic leukemia (ALL) patients comprise a highly immunocompromised group due to factors associated either with the treatment or the disease itself.
Christos Stafylidis +4 more
doaj +1 more source
Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes [PDF]
We evaluated the in vitro activity of manogepix against Fusarium oxysporum and Fusarium solani species complex (FOSC and FSSC, respectively) isolates per CLSI document M38 broth microdilution methods.
Hamid Badali +7 more
openaire +2 more sources

